GoodRx Holdings (GDRX) Stock Overview
Offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
GDRX Community Fair Values
Create NarrativeSee what 28 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
GoodRx Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.38 |
| 52 Week High | US$5.81 |
| 52 Week Low | US$1.77 |
| Beta | 1.6 |
| 1 Month Change | -2.03% |
| 3 Month Change | 26.59% |
| 1 Year Change | -16.95% |
| 3 Year Change | -38.21% |
| 5 Year Change | -92.10% |
| Change since IPO | -93.31% |
Recent News & Updates
Narrative Update • Sep 04
GDRX: Membership Expansion And GLP 1 Momentum Will Reset Prescription Economics
Analysts have nudged GoodRx Holdings' fair value estimate to $5.00 from $4.00, citing updated models that reflect recent Q2 results, higher price targets across several firms in the $3.75 to $5.00 range, and interest in areas such as GLP-1 driven Pharma Direct volumes. Analyst Commentary Recent Street research on GoodRx Holdings points to a more constructive tone, with several bullish analysts lifting price targets into a tighter band between $3.75 and $5.00.
Narrative Update • Aug 21
GDRX: Pharma Direct GLP-1 Momentum And New Offerings Will Drive Future Upside
GoodRx Holdings' analyst price target has increased, moving from about $3.18 to roughly $4.03. Analysts point to updated models following Q2 results, including stronger GLP-1 momentum in Pharma Direct and revised views on sector peers.Seeking Alpha • Aug 12
GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope
Summary GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation reflects these improvements. I remain marginally more positive, yet GDRX still presents considerable risk, warranting a continued neutral rating. Despite operational progress, risk-reward remains balanced at current valuations, justifying a cautious stance. Read the full article on Seeking AlphaRecent updates
Narrative Update • Sep 04
GDRX: Membership Expansion And GLP 1 Momentum Will Reset Prescription Economics
Analysts have nudged GoodRx Holdings' fair value estimate to $5.00 from $4.00, citing updated models that reflect recent Q2 results, higher price targets across several firms in the $3.75 to $5.00 range, and interest in areas such as GLP-1 driven Pharma Direct volumes. Analyst Commentary Recent Street research on GoodRx Holdings points to a more constructive tone, with several bullish analysts lifting price targets into a tighter band between $3.75 and $5.00.Narrative Update • Aug 21
GDRX: Pharma Direct GLP-1 Momentum And New Offerings Will Drive Future Upside
GoodRx Holdings' analyst price target has increased, moving from about $3.18 to roughly $4.03. Analysts point to updated models following Q2 results, including stronger GLP-1 momentum in Pharma Direct and revised views on sector peers.Seeking Alpha • Aug 12
GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope
Summary GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation reflects these improvements. I remain marginally more positive, yet GDRX still presents considerable risk, warranting a continued neutral rating. Despite operational progress, risk-reward remains balanced at current valuations, justifying a cautious stance. Read the full article on Seeking Alpha
Narrative Update • Aug 07
GDRX: Rising Wegovy Reliance Will Pressure Future Prescription Margin Sustainability
Analysts have lifted their price target on GoodRx Holdings to $5 from $3.50, reflecting updated views on fair value, growth assumptions and profit potential, supported by recent research highlighting factors such as Wegovy prescription activity and revised earnings estimates. Analyst Commentary on GoodRx Holdings Recent research on GoodRx highlights a mixed tone.Narrative Update • Jul 07
GDRX: Membership Expansion And Higher Margins Will Reset Prescription Economics
Analysts have increased their price target for GoodRx Holdings to $4.00 from $3.50, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E that are consistent with recent research commentary from multiple firms. Analyst Commentary Recent research on GoodRx Holdings points to a more constructive tone, with several bullish analysts updating their assumptions and using higher price targets that align with the revised US$4.00 fair value estimate.Narrative Update • Jun 23
GDRX: Higher Fair Value Assumptions Will Strain Core Prescription Economics
Analysts have lifted their GoodRx Holdings price target by $0.25 to reflect updated views on fair value, discount rate, revenue growth, profit margin, and future P/E metrics, supported by recent target increases from major firms to around $4 per share. Analyst Commentary on GoodRx Holdings Recent research on GoodRx Holdings centers on how the current share price lines up with updated views on fair value, earnings power, and execution risks.Narrative Update • Jun 09
GDRX: Pharma Direct Shift And New Offerings Will Support Future Upside
Analysts have lifted their GoodRx Holdings price targets by about $0.50 to $1, with recent moves to $4 from $3.50 at Citi and similar $1 increases at TD Cowen and Goldman Sachs. These changes reflect updated views on the stock's risk, growth, profitability and future P/E assumptions.Narrative Update • May 26
GDRX: Pharma Direct Shift Will Support Future Upside Despite Prescription Reset
GoodRx Holdings' analyst price target has moved higher, with recent revisions pointing toward $4 as analysts factor in updated views on revenue growth, profit margins, and a lower discount rate following fresh research from Citi, TD Cowen, and Goldman Sachs. Analyst Commentary Recent research shows a split view on GoodRx Holdings, with some analysts lifting price targets toward US$4 while others trim expectations and ratings following updated guidance and business mix changes.Analysis Article • May 14
Some May Be Optimistic About GoodRx Holdings' (NASDAQ:GDRX) Earnings
The market was pleased with the recent earnings report from GoodRx Holdings, Inc. ( NASDAQ:GDRX ), despite the profit...Narrative Update • May 06
GDRX: Pharma Direct And Take Rate Reset Will Reframe Prescription Economics
Narrative Update on GoodRx Holdings Analysts have reset the consensus price target for GoodRx to $3.50, down sharply from prior targets that ranged from $4 to $7, citing pressure on Prescription Transaction economics, a reset in take rates, and increased focus on the Pharma Direct business as key drivers of the change. Analyst Commentary Street research has shifted sharply lower on GoodRx's valuation, with price targets now clustered in a US$2 to US$3.50 range.Narrative Update • Apr 22
GDRX: Take Rate Reset Will Pressure Core Prescription Economics Ahead
Analysts have reduced GoodRx's consensus price targets significantly to a range of $2 to $3.50, citing reset take rates in the core prescription business, pressure on near term growth and margins, and a greater focus on Pharma Direct and branded drugs. Analyst Commentary Street research on GoodRx has turned more cautious, with a series of reduced price targets clustering between $2 and $3.50.Narrative Update • Apr 07
GDRX: Pharma Direct Pivot Will Reframe Prescription Headwinds Going Forward
Analysts have reset GoodRx's fair value and price targets sharply lower, with the average target moving from about $7.00 toward $3.50 as they factor in a higher discount rate, softer revenue growth and margin expectations, and a higher assumed future P/E multiple driven by pressure on the core prescription business alongside potential support from Pharma Direct. Analyst Commentary Recent research updates cluster around a consistent message: lower fair value estimates for GoodRx, but with a split between cautious and more constructive views on the path forward.Narrative Update • Mar 23
GDRX: Pharma Direct And Pharmacy Partnerships Will Drive Future Upside
Analysts have cut their average price targets for GoodRx to a range of about $2 to $3.50, citing a take rate reset that pressures near term growth and margins in the core Prescription Transaction business, while pointing to Pharma Direct as a key source of potential upside. Analyst Commentary Recent Street research on GoodRx reflects a wide reset in expectations, with lower price targets across the board and mixed views on the company’s ability to execute through the take rate reset and business shift toward Pharma Direct and branded drugs.Narrative Update • Mar 09
GDRX: Prescription Take-Rate Reset Will Drive A Tougher Outlook
Analysts cut their fair value estimate for GoodRx to $1.90 from $2.60 and lowered price targets into a $2 to $3.50 range, citing structural take-rate headwinds in the prescription business, pressure on near-term growth and margins, and an increased emphasis on Pharma Direct and branded drugs. Analyst Commentary Recent Street research on GoodRx highlights a clear reset in expectations, with multiple bearish analysts trimming price targets and shifting ratings in response to pressure on the core prescription discount business and uncertainty around the pivot to Pharma Direct and branded drugs.Narrative Update • Feb 23
GDRX: TrumpRx And Pharmacy Partnerships Will Support Future Upside
Analysts have trimmed their price targets on GoodRx Holdings, with one key cut to $4.50 from $5. This reflects caution around near term TrumpRx monetization while still noting potential longer term upside for the health tech and distribution group.Narrative Update • Feb 08
GDRX: Weight Loss Partnerships And PBM Role Will Support Future Upside
Analysts have trimmed their price targets on GoodRx, and our updated fair value estimate reflects this shift with a move from about US$4.95 to roughly US$4.56. This change comes as they factor in a slightly higher discount rate, a modestly lower assumed future P/E multiple, and only small tweaks to revenue growth and profit margin assumptions.Narrative Update • Jan 24
GDRX: Pharmacy Headwinds And Weight Loss Efforts Will Shape Fairly Balanced Outlook
Narrative Update on GoodRx Holdings The analyst price target for GoodRx has been trimmed by a few dollars into the low single digits. Analysts generally point to ongoing headwinds in health tech, pharmacy closures, and reimbursement changes, while also acknowledging progress in new offerings and partnerships that could take years to fully influence results.Narrative Update • Jan 10
GDRX: Pharmacy Headwinds And Weight Loss Expansion Will Shape Balanced Outlook
Analysts have eased their price expectations for GoodRx, with the updated target range implied by recent cuts from US$7 to between US$3 and US$6, and an updated fair value input of 2.6, reflecting higher discount rates and more conservative P/E assumptions, even as they cite progress in partnerships and new offerings. Analyst Commentary Recent Street research around GoodRx has centered on lower price targets and a more cautious stance on how quickly new products and partnerships might translate into value for shareholders.Narrative Update • Dec 16
GDRX: Expanding Weight Loss Collaborations Will Drive Future Upside Despite Pharmacy Headwinds
Analysts have modestly trimmed their average price target on GoodRx, reflecting a slightly lower fair value estimate of about $4.95 per share. They are balancing cautious views on pharmacy headwinds and reimbursement changes against emerging, but longer-dated, upside from new partnerships, including weight-loss and PBM initiatives.Narrative Update • Dec 02
GDRX: Expanding Partnerships Will Drive Share Upside Amid Evolving Pharmacy Landscape
Analysts have lowered their price targets for GoodRx Holdings, with recent reductions from $7 to $6, $5 to $4, and $3.40 to $3. This reflects cautious sentiment about headwinds in the pharmacy ecosystem, even though there is some optimism over new partnerships and offerings.Narrative Update • Nov 18
GDRX: Future Partnerships Will Drive Long-Term Upside Despite Industry Uncertainty
The analyst price target for GoodRx Holdings has been reduced from approximately $5.37 to $5.09 per share. Analysts cite ongoing headwinds in the pharmacy ecosystem but acknowledge some positive developments in new partnerships and offerings.Analysis Article • Nov 01
Investors Don't See Light At End Of GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Tunnel And Push Stock Down 33%
GoodRx Holdings, Inc. ( NASDAQ:GDRX ) shareholders won't be pleased to see that the share price has had a very rough...Analysis Article • Oct 02
Should You Think About Buying GoodRx Holdings, Inc. (NASDAQ:GDRX) Now?
GoodRx Holdings, Inc. ( NASDAQ:GDRX ), is not the largest company out there, but it led the NASDAQGS gainers with a...Analysis Article • Aug 15
GoodRx Holdings' (NASDAQ:GDRX) Performance Is Even Better Than Its Earnings Suggest
GoodRx Holdings, Inc.'s ( NASDAQ:GDRX ) earnings announcement last week was disappointing for investors, despite the...Narrative Update • Aug 08
Digital Health And Telemedicine Expansion Will Deepen Market Opportunity
The decrease in GoodRx Holdings' consensus price target is primarily driven by a notable decline in future P/E multiples and an increased discount rate, resulting in a revised fair value of $5.91. What's in the News GoodRx issued 2025 revenue guidance, expecting an increase over 2024’s $792.3 million.Analysis Article • Aug 08
Little Excitement Around GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Revenues As Shares Take 28% Pounding
GoodRx Holdings, Inc. ( NASDAQ:GDRX ) shareholders won't be pleased to see that the share price has had a very rough...Analysis Article • Jun 24
GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
GoodRx Holdings, Inc. ( NASDAQ:GDRX ) shareholders would be excited to see that the share price has had a great month...Analysis Article • May 23
GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...
New Narrative • May 01
Pharma Manufacturer Solutions Expansion Will Improve Prescription Access
GoodRx aims to boost revenue by expanding Pharma Manufacturer Solutions and enhancing the prescription marketplace, aligning with partners' economic needs.Seeking Alpha • Mar 24
GoodRx: Great Value For Patient Investors (Upgrade)
Summary GoodRx is a great small-cap value stock to buy amid the recent downturn. I'm upgrading the stock to a buy. GoodRx showcases strong adjusted EBITDA despite slower growth, making it an attractive target for private equity deals as public equities become less appealing. The company's new CEO is driving a wholesale change in business strategy, chasing relationships directly with pharmaceutical manufacturers. Management is expecting an acceleration in revenue growth in FY25 (relative to just 1% growth in Q4), driven in part by the lapse of a tough Kroger comp midway through next year. Read the full article on Seeking AlphaShareholder Returns
| GDRX | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -5.1% | -0.1% | -0.1% |
| 1Y | -17.0% | -18.1% | 11.9% |
Return vs Industry: GDRX exceeded the US Healthcare Services industry which returned -18.1% over the past year.
Return vs Market: GDRX underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| GDRX volatility | |
|---|---|
| GDRX Average Weekly Movement | 7.1% |
| Healthcare Services Industry Average Movement | 10.4% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: GDRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GDRX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 697 | Wendy Barnes | www.goodrx.com |
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform.
GoodRx Holdings, Inc. Fundamentals Summary
| GDRX fundamental statistics | |
|---|---|
| Market cap | US$1.15b |
| Earnings (TTM) | US$16.25m |
| Revenue (TTM) | US$785.23m |
71.0x
P/E Ratio1.5x
P/S RatioIs GDRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GDRX income statement (TTM) | |
|---|---|
| Revenue | US$785.23m |
| Cost of Revenue | US$72.04m |
| Gross Profit | US$713.19m |
| Other Expenses | US$696.94m |
| Earnings | US$16.25m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.048 |
| Gross Margin | 90.83% |
| Net Profit Margin | 2.07% |
| Debt/Equity Ratio | 75.1% |
How did GDRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 20:35 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GoodRx Holdings, Inc. is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Allen Lutz | BofA Global Research |
| Daniel Grosslight | Citigroup Inc |